Sam Brusco, Associate Editor07.13.22
Orthobiologics firm Bone Solutions Inc. (BSI) has earned U.S. Food and Drug Administration (FDA) 510(k) clearance expanding indications for its Mg OSTEOINJECT drillable, adhesive, injectable bone void filler that incorporates magnesium for bone health and development.
The clearance expands the material’s indication to use as an adjunct to hardware fixation by supporting bone fragments during the surgical procedure.
Mg OSTEOINJECT is also a minimally invasive treatment for insufficiency and micro fractures via percutaneous skeletal fixation. Its adhesive properties and unique resorption profile provide stability, boosting cell proliferation and mineralization that results in enhance regeneration of bone in many orthopedic applications.
The clearance expands the material’s indication to use as an adjunct to hardware fixation by supporting bone fragments during the surgical procedure.
Mg OSTEOINJECT is also a minimally invasive treatment for insufficiency and micro fractures via percutaneous skeletal fixation. Its adhesive properties and unique resorption profile provide stability, boosting cell proliferation and mineralization that results in enhance regeneration of bone in many orthopedic applications.